World Pharma News Digest

Teva Receives Positive Feedback on Second AOK Tender in Germany
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced that it
has received notification from Allgemeinen Ortskrankenkassen (AOK),
Germany's largest health insurance company, on the results of the most
recent tender for finished dosage pharmaceutical products. Teva is
very pleased to have been awarded a significant increase in the number
of molecules for which it can contract to supply during 2008-2009;
compared to the six products it was awarded in the first tender
earlier this year.
Read more...
http://www.worldpharmanews.com/content/view/114/1/

ASCO Journals to be accessible through SIMID® S.M.I.L.E.
SIMID® announced that the American Society of Clinical Oncology (ASCO)
has agreed to provide metadata and full-text articles from its
portfolio of medical journals through the SIMID Scientific Medical
Information Library Europe (S.M.I.L.E.) database.
Read more...
http://www.worldpharmanews.com/content/view/113/1/

The Bill & Melinda Gates Foundation New Grants to Fight Tuberculosis
Epidemic
The Bill & Melinda Gates Foundation announced grants totaling $280
million to help fight tuberculosis, an epidemic that infects one-third
of people on earth and kills nearly 2 million yearly - mostly in the
poorest countries. The 11 new grants will speed research and
development on promising vaccines, diagnostic tests, and treatments to
help reduce the global TB burden.
Read more...
http://www.worldpharmanews.com/content/view/112/1/

Novo Nordisk receives approval in the EU for use of NovoRapid® in
elderly people
Novo Nordisk today announced that the European Commission has approved
the rapid-acting insulin NovoRapid® (insulin aspart) for treatment of
diabetes in the elderly and in people with renal or hepatic
impairment.
Read more...
http://www.worldpharmanews.com/content/view/111/1/

Spending on Cancer Research in Europe Rising
Spending on cancer research in Europe is on the up, and Europe is now
a major contributor to the global cancer research effort, according to
the second cancer research funding survey by the European Cancer
Research Managers (ECRM) Forum. However, growing levels of bureaucracy
threaten to stifle future research, the report warns.
Read more...
http://www.worldpharmanews.com/content/view/110/1/

FDA Warns Procter & Gamble about Unlawful Marketing of Product for
School Children
The U.S. Food and Drug Administration (FDA) sent a warning letter to
Procter & Gamble for making unlawful claims about its Vicks Early
Defense Foaming Hand Sanitizer (Early Defense) product. The agency
says the product's claims and directions for use cause it to be an
unapproved new drug under the Federal Food, Drug, and Cosmetic Act. It
cited specifically Procter & Gamble promotion of Early Defense for use
by schoolchildren to prevent colds and to provide antimicrobial
activity for up to three hours.
Read more...
http://www.worldpharmanews.com/content/view/109/1/

Call for Abstracts - 3rd International Conference on HIV Treatment
Adherence
March 17-18, 2008
Hyatt Regency Hotel, Jersey City, NJ
Adherence to medical treatment for HIV/AIDS is an essential
determinant of treatment success or failure. Yet, we still have much
to learn about measurement, determinants, and interventions for HIV
treatment adherence - these are complex challenges that require
multidisciplinary cooperation among providers, researchers, government
agencies, and patients.
Read more...
http://www.worldpharmanews.com/content/view/108/1/

Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New
HIV Drug
Nearly three times as many patients receiving Selzentry, in addition
to an optimized background regimen, achieved undetectable levels of
HIV virus compared with those receiving an optimized regimen alone,
according to 48 week data presented today in late-breaking sessions at
the Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC) meeting. This newly approved CCR5 antagonist - the first new
class of oral HIV medicines introduced in more than ten years - is now
available throughout the U.S.
Read more...
http://www.worldpharmanews.com/content/view/107/1/

AstraZeneca launches and prices a EUR750 million debut eurobond
AstraZeneca PLC, rated A1 (stable) by Moody's and AA- (stable) by
Standard & Poor's, priced a successful debut eurobond transaction (the
"Bonds") issuing a total of EUR750 million. The proceeds of the issue
will be used for general corporate purposes and to repay a portion of
the outstanding US commercial paper taken on in connection with the
acquisition of MedImmune.
Read more...
http://www.worldpharmanews.com/content/view/106/1/

Study Results for Aclidinium Bromide, a Novel Anticholinergic
Forest Laboratories (NYSE: FRX) announced today that single doses of
inhaled aclidinium produced a significant bronchodilatory response in
17 patients with COPD according to results of a phase IIa trial
presented today at the European Respiratory Society (ERS) Annual
Congress in Stockholm.(1)
Read more...
http://www.worldpharmanews.com/content/view/105/1/

Best regards,
Ruslan David, MD
eHealthNews.EU Portal & World Pharma News
Administrator/Editor
http://www.ehealthnews.eu
http://www.worldpharmanews.com

.

Relevant Pages

  • World Pharma News Digest
    ... Teva Receives Positive Feedback on Second AOK Tender in Germany ... Information Library Europe database. ... Spending on cancer research in Europe is on the up, ... Call for Abstracts - 3rd International Conference on HIV Treatment ...
    (sci.med)
  • Re: Antidepressants: The spectrum beyond depression
    ... Breast cancer drug Tamoxifen could be an unlikely new treatment for manic depression. ... Research from the National Institute of Cancer Research in Bethesda, Maryland, show that Tamoxifen blocks protein kinase C, which is overactive in brain cells during the manic phase of bipolar disorder, and seems to calm patients much quicker than conventional treatments. ...
    (uk.people.support.depression)
  • Hitlary Adds ANOTHER $300 Million to Her Tax Increases on Innocent Americans!
    ... WASHINGTON -- A proposal by Democrat Hillary Rodham Clinton would provide $300 million a year in increased government funding on breast cancer research, focusing on treatment and exploring possible genetic and environmental triggers for the disease. ...
    (alt.politics)